How Does Givlaari Work? Mechanism of Action Explained in Plain English

Givlaari (givosiran) belongs to an entirely new class of medicines called RNA interference (RNAi) therapeutics — a category so novel that it barely existed a decade ago. Understanding how it works helps explain why it's effective, why it must be given as an injection (not a pill), and why it takes aim at the disease rather than just the symptoms.

You don't need a biology degree to understand the concept. This guide explains it step by step.

The Problem: What Causes AHP Attacks?

To understand how Givlaari works, you first need to understand what goes wrong in acute hepatic porphyria (AHP).

Your body continuously makes heme — a molecule that lives inside hemoglobin in your red blood cells and helps carry oxygen. The liver produces heme through a multi-step biochemical pathway, like an assembly line. The very first step of this assembly line is controlled by an enzyme called ALAS1 (delta-aminolevulinate synthase 1).

In people with AHP, a genetic mutation causes a deficiency in one of the downstream enzymes in the heme assembly line. When ALAS1 (the first enzyme) is triggered — by things like certain medications, fasting, alcohol, infections, or hormonal changes — it revs up the assembly line. Normally, the downstream enzymes can handle the increased flow. But in AHP, the bottleneck enzyme can't keep up. The result is a toxic backup: chemicals called ALA (aminolevulinic acid) and PBG (porphobilinogen) accumulate. These compounds are neurotoxic — they damage nerve cells, causing the agonizing symptoms of a porphyria attack.

The Solution: Turn Down the ALAS1 Switch

Since overactivation of ALAS1 is what drives the toxic buildup, the logical solution is to turn down ALAS1 — reduce how much of that enzyme your liver makes. That's exactly what Givlaari does, using RNA interference.

How RNA Interference (RNAi) Works — In Plain English

Here's the basic biology:

1. DNA in your cells contains the genetic instructions for making proteins (including enzymes like ALAS1). These instructions are read and copied into a messenger molecule called mRNA (messenger RNA).
2. The mRNA travels out of the cell nucleus and acts as a blueprint that tells the cell's protein-making machinery to build a specific protein — in this case, ALAS1.
3. Givlaari is a synthetic small interfering RNA (siRNA) — a tiny double-stranded molecule that is a perfect match for the ALAS1 mRNA sequence.
4. When Givlaari reaches a liver cell, it triggers the cell's own natural defense system (called RISC — RNA-induced silencing complex). RISC uses Givlaari as a guide to find ALAS1 mRNA and destroy it.
5. With the ALAS1 mRNA destroyed, the cell can't build as much ALAS1 enzyme. Less ALAS1 = lower activation of the heme assembly line = less ALA and PBG building up = fewer attacks.

Think of it like intercepting the instruction manual before the factory can act on it. Givlaari doesn't fix the broken enzyme downstream (it doesn't change your DNA). Instead, it reduces the overwhelming demand at the top of the pipeline, allowing the limited downstream enzymes to keep up with a smaller load.

How Does Givlaari Find the Liver?

A critical challenge with any RNA-based drug is getting it to the right organ and into the right cells. The ALAS1 gene is active in the liver, so Givlaari needs to reach liver cells (hepatocytes) specifically.

Alnylam solved this problem by attaching Givlaari to a targeting molecule made of three units of N-acetylgalactosamine (GalNAc). Hepatocytes have an abundance of receptors on their surface (called ASGPR — asialoglycoprotein receptors) that bind GalNAc with very high affinity. When Givlaari is injected subcutaneously, it travels through the bloodstream to the liver, where the GalNAc ligand locks onto the ASGPR receptors on hepatocytes like a key into a lock. The cell then takes up Givlaari through endocytosis (engulfing it), bringing it inside where it can do its silencing work.

This targeted delivery system is what allows Givlaari to work from a subcutaneous injection — and why it acts specifically on the liver without requiring intravenous infusion.

Why Once Monthly?

The RISC machinery continues to destroy ALAS1 mRNA for weeks after Givlaari is administered. A single dose provides meaningful suppression of ALAS1 for approximately 30 days — which is why the dosing schedule is once monthly. This is a significant advantage over intravenous hemin, which requires daily infusions for acute attacks and weekly-to-monthly infusions for prophylaxis.

Givlaari vs. Hemin: Different Mechanisms, Different Roles

Hemin (Panhematin) works by a different mechanism. It provides the final product of the heme pathway directly to the liver, which signals ALAS1 to stop revving up (negative feedback). It's effective for acute attacks but requires repeated IV infusions and doesn't provide the sustained, once-monthly silencing that Givlaari does. Patients on Givlaari can still use hemin to treat breakthrough attacks.

For a complete overview of Givlaari including dosage and access information, see What Is Givlaari? Uses, Dosage, and What You Need to Know.

If you've been prescribed Givlaari and need help finding where to receive your monthly injection, medfinder contacts specialty pharmacies and administration sites on your behalf.